Orexo AB announces that Robin Wright resigns as CFO

Orexo AB announces that Robin Wright resigns as CFO

Uppsala, April 11, 2011 - Orexo AB (STO: ORX) announces today that Robin
Wright has decided to leave the company and resign from the position of
Chief Financial Officer as of April 30.

The process of finding a new Chief Financial Officer has been initiated.

Anders Lundström, President and CEO of Orexo:
“We have greatly appreciated Robin's contributions to the company's
success during the last three years. His extensive experience has been
of great value, both in his role as CFO and as Head of Business
Development. I wish him the best in his future endeavours.”

 

Contact details:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
Email: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

 

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Orexo is developing proprietary products based on
its proven reformulation technologies, targeted at the Specialty
Pharmaceutical market. Orexo intends to commercialise some of these
products itself in one or more major markets. Its development activity
builds on Orexo's core competences in R&D, which have previously
resulted in several successful products, currently out-licensed through
worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which Abstral is a
leading product for the treatment of breakthrough pain in cancer
patients in most of Europe and now also in the United States. Orexo also
has three significant partnerships with major pharmaceutical companies
for research and development programs: discovery stage collaborations
with Ortho-McNeil Janssen and Janssen Pharmaceutica in respiratory
inflammation and with Boehringer Ingelheim for inflammation and pain,
both within the arachidonic acid cascade and a clinical stage
development agreement with Novartis for the treatment of
gastrointestinal disorders. Orexo's head office is located in Uppsala,
Sweden. More information can be found at
www.orexo.com (http://www.orexo.com/).

 

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 11, 2011 at 1:00 pm CEST.